{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:13:43Z","timestamp":1791764023000,"version":"4.3.4"},"reference-count":14,"publisher":"BMJ","issue":"8","funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paul and Evanina Mackall Foundation"},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30 EY006360"],"award-info":[{"award-number":["P30 EY006360"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Pennsylvania Core Grant for Vision Research","award":["2P30EY001583"],"award-info":[{"award-number":["2P30EY001583"]}]},{"name":"National Institutes of Health K23","award":["1K23EY025729 - 01"],"award-info":[{"award-number":["1K23EY025729 - 01"]}]},{"DOI":"10.13039\/501100000262","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","award":["CD-C-0918-0748-EEC"],"award-info":[{"award-number":["CD-C-0918-0748-EEC"]}],"id":[{"id":"10.13039\/501100000262","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec><jats:title>Background\/Aims<\/jats:title><jats:p>A series at a single clinical centre recently demonstrated an association between the interstitial cystitis drug pentosan polysulfate sodium (PPS) and a vision-threatening pigmentary maculopathy. The aim of this study was to determine if an association exists between PPS use and macular disease in a large national cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective, matched cohort study using data from a large US medical claims database from 2002 to 2016 was performed. A total of 3012 and 1604 PPS users were compared with 15\u2009060 and 8017 matched controls at 5 and 7 years, respectively. The primary outcome measures included (1) any new diagnosis of a hereditary or secondary pigmentary maculopathy (atypical maculopathy outcome), and (2) any new diagnosis of dry age-related macular degeneration (AMD) or drusen in addition to the aforementioned diagnoses (atypical maculopathy+AMD outcome).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At the 5-year and 7-year follow-up, 9 (0.3%) and 10 (0.6%) PPS patients progressed to the atypical maculopathy outcome compared with 32 (0.2%) and 25 (0.3%) control patients, respectively. 103 (3.4%) and 87 (5.4%) PPS patients developed the atypical maculopathy+AMD outcome compared with 440 (2.9%) and 328 (4.1%) control patients at 5 and 7 years, respectively. At 5 years, multivariate analysis showed no significant association (p&gt;0.13). At 7 years, PPS users had significantly increased odds of having the atypical maculopathy+AMD outcome (OR=1.41, 95% CI 1.09 to 1.83, p=0.009).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PPS exposure was associated with a new diagnosis of macular disease at the 7-year follow-up in a large national cohort.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2019-314765","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T22:15:23Z","timestamp":1573078523000},"page":"1093-1097","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":59,"title":["Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort"],"prefix":"10.1136","volume":"104","author":[{"given":"Nieraj","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5235-6741","authenticated-orcid":false,"given":"Alexa L","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L","family":"VanderBeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2020080315452628000_104.8.1093.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00179-9"},{"key":"2020080315452628000_104.8.1093.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.086"},{"key":"2020080315452628000_104.8.1093.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00845-1"},{"key":"2020080315452628000_104.8.1093.4","unstructured":"American Urological Association . Diagnosis and treatment interstitial cystitis\/bladder pain syndrome guideline, 2014. Available: https:\/\/www.auanet.org\/guidelines\/interstitial-cystitis-(ic\/bps)-guideline [Accessed 7 Sep 2019]."},{"key":"2020080315452628000_104.8.1093.5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ophtha.2018.04.026","article-title":"Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium","volume":"125","author":"Pearce","year":"2018","journal-title":"Ophthalmology"},{"key":"2020080315452628000_104.8.1093.6","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ophtha.2019.04.024","article-title":"Strength of association between pentosan polysulfate and a novel maculopathy","volume":"126","author":"Hanif","year":"2019","journal-title":"Ophthalmology"},{"key":"2020080315452628000_104.8.1093.7","doi-asserted-by":"crossref","unstructured":"Hanif AM , Armenti ST , Taylor SC , et al . Phenotypic spectrum of pentosan polysulfate sodium\u2013associated maculopathy. JAMA Ophthalmol 2019.doi:10.1001\/jamaophthalmol.2019.3392","DOI":"10.1001\/jamaophthalmol.2019.3392"},{"key":"2020080315452628000_104.8.1093.8","unstructured":"Pharmaceuticals J . Elmiron (R) [package insert]."},{"key":"2020080315452628000_104.8.1093.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00714-0"},{"key":"2020080315452628000_104.8.1093.10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/IIO.0000000000000262","article-title":"Pattern dystrophy: an imprecise diagnosis in the age of precision medicine","volume":"59","author":"Hanif","year":"2019","journal-title":"Int Ophthalmol Clin"},{"key":"2020080315452628000_104.8.1093.11","unstructured":"Multum C . Pentosan polysulfate sodium, 2018. Available: https:\/\/www.drugs.com\/mtm\/pentosan-polysulfate-sodium.html#Dosage [Accessed 20 Feb 2019]."},{"key":"2020080315452628000_104.8.1093.12","unstructured":"Drugs.com . Elmiron prices, Coupons and patient assistance programs. Available: https:\/\/www.drugs.com\/price-guide\/elmiron [Accessed 20 Feb 2019]."},{"key":"2020080315452628000_104.8.1093.13","doi-asserted-by":"crossref","unstructured":"Sinnott SJ , Buckley C , O\u2032Riordan D , et al . The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS One 2013;8:e64914.doi:10.1371\/journal.pone.0064914","DOI":"10.1371\/journal.pone.0064914"},{"key":"2020080315452628000_104.8.1093.14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.juro.2018.06.076","article-title":"Re: FDA BRUDAC 2018 Criteria for Interstitial Cystitis\/Bladder Pain Syndrome Clinical Trials: Future Direction for Research: J. C. Nickel and R. Moldwin J Urol 2018;200:39-42","volume":"200","author":"Pearce","year":"2018","journal-title":"J Urol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2019-314765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T09:01:29Z","timestamp":1601110889000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2019-314765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,7,23]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bjophthalmol-2019-314765"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314765","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]}}}